GSK PLC GLAXF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
GSK Says FDA Approved Jemperli For Certain Types of Rectal Cancer
-
GSK Says Lung-Cancer Drug Shows Benefits in Global Trial
-
Flu season is already here. Here's what to know about this year's flu shots.
-
European Pharma Leaders Push for National Reforms to Boost Investment
-
Is the shingles vaccine the secret to living longer and delaying dementia? Here's what the science says.
-
GSK Says New Lung-Cancer Drug Shows Benefits at Earlier Stage of Treatment
-
Hutchmed Enters Licensing Agreement With GSK for Cancer Drug
-
GSK Moves mRNA Flu Vaccine Candidate to Late-Stage Trial
Trading Information
- Previous Close Price
- $24.44
- Day Range
- $23.70–24.74
- 52-Week Range
- $20.80–31.48
- Bid/Ask
- $23.21 / $26.17
- Shares Outstanding
- 4.01B
- Market Cap
- $99.33B
- Volume/Avg
- 560 / 2,336
Key Statistics
- Price/Earnings (Normalized)
- 12.19
- Price/Sales
- 2.27
- Dividend Yield (Trailing)
- 3.67%
- Dividend Yield (Forward)
- 3.63%
- Dividend Payment Schedule
- Jan, Apr, Jul, Oct
- Total Yield
- 5.29%
Company Profile
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 66,841
- Website
- https://www.gsk.com
Competitors
Valuation
|
Metric
|
GLAXF
|
MRK
|
AZN
|
|---|---|---|---|
Price/Earnings (Normalized) | 12.19 | 44.74 | 15.16 |
Price/Book Value | 4.24 | 8.46 | 5.07 |
Price/Sales | 2.27 | 5.35 | 4.24 |
Price/Cash Flow | 9.70 | 16.08 | 16.77 |
Price/Earnings
GLAXF
MRK
AZN
Financial Strength
|
Metric
|
GLAXF
|
MRK
|
AZN
|
|---|---|---|---|
Quick Ratio | 0.52 | 0.71 | 0.66 |
Current Ratio | 0.82 | 1.32 | 0.89 |
Interest Coverage | 9.51 | 4.28 | 7.99 |
Quick Ratio
GLAXF
MRK
AZN
Profitability
|
Metric
|
GLAXF
|
MRK
|
AZN
|
|---|---|---|---|
Return on Assets (Normalized) | 11.66% | 6.27% | 9.00% |
Return on Equity (Normalized) | 42.98% | 16.68% | 21.69% |
Return on Invested Capital (Normalized) | 22.63% | 9.82% | 14.36% |
Return on Assets
GLAXF
MRK
AZN
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|w$!j$#N% | LOCK|<^ | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|GcW#H! | LOCK|JD& | $612B | |||
| AbbVie Inc
ABBV
| LOCK|@gs?PM | LOCK|x> | $500B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|^#f%r$jz | LOCK|XD | $368B | |||
| Merck & Co Inc
MRK
| LOCK|HXB%FH | LOCK|wd< | $354B | |||
| Novartis AG ADR
NVS
| LOCK|M!WF>?XZ | LOCK|ps^ | $287B | |||
| AstraZeneca PLC
AZN
| LOCK|L!@rx@X | LOCK|@^r | $256B | |||
| Amgen Inc
AMGN
| LOCK|y#&<L%n@ | LOCK|<^< | $230B | |||
| Gilead Sciences Inc
GILD
| LOCK|<#>Q@V | LOCK|^@@ | $190B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|gcv##@? | LOCK|BR# | $170B |
United States